Lotus Eye Hospital And Institute Ltd.
Snapshot View

49.65 -2.35 ▼-4.5%

25 May 2022, 04:01:00 PM
Volume: 343

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.lotuseye.org
Market Cap 106.17 Cr.
Enterprise Value(EV) 92.65 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 1.71 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 29.89 Trailing Twelve Months Ending 2021-12
Industry PE 38.69 Trailing Twelve Months Ending 2021-12
Book Value / Share 26.00 Trailing Twelve Months Ending 2021-12
Price to Book Value 1.96 Calculated using Price: 51.05
Dividend Yield 0.98 Period Ending 2021-03
No. of Shares Subscribed 2.08 Cr. 20,796,330 Shares
FaceValue 10
Company Profile

Lotus Eye Care Hospital  was originally incorporated as ‘Kalaivani Health Centre Pvt. Ltd.’on March 14,1997 under the Companies Act, 1956 vide Certificate of Incorporation issued by the Registrar of Companies, Tamil Nadu, Coimbatore. The name of the Company was changed to ‘Lotus Eye Care Hospital Pvt. Ltd. on January 23, 2006 and subsequently to ‘Lotus Eye Care Hospital Limited’ upon conversion into Public Limited Company on October 16, 2007 and a fresh certificate of incorporation has been obtained from Registrar of Companies, Tamil Nadu, Coimbatore.

Lotus Eye Care Hospital is a hi-tech super specialty eye care hospital catering its value added service to the society since inception

Lotus is known for its excellence in Ophthalmic services with personalized care. Lotus is committedly pioneering in the technological revolution in eye care and rendering service to thousands of patients from across the globe to see the world better than ever before.

In the year 1998 Lotus introduced Multi Scan Lasik and in the year 2002 Wave front based Esiris Custom Lasik for the first time in India. Lotus was the first Eye Hospital in South East Asia to have performed Epilasik in July 2004. In the year June 2005 Lotus introduced the most advanced technology of Zyoptix Z100 and combined two superior technologies Epilasik and Zyoptix known as Zyoptix Integrated Epilasik to achieve Supervision.

Lotus has a vision of “empowering eyes to illuminate lives”. Lotus Eye Care group is marching towards its vision of becoming India’s best Corporate Hospital with branches in strategic locations where quality eye care is in need, and render world class eye care service to the society.

Dr.SK.Sundaramoorthy and his team of ophthalmic experts, who have highly qualified with vast experience in each specialty, render comprehensive eye care to hundreds of patients daily at their state of the art eye hospitals in Coimbatore, Tirupur and Salem in South India.

Services offered by the company:

  • Specialty Treatments 
  • Institute of Optometry 
  • Community ophthalmology  
  • Medical Tourism
  • Eye Bank

Milestones:

  • 1989- Opening of hospital at R.S.Puram, Coimbatore. The same was under management of LVRT from 1992 to 2006.
  • 2002- Opening of hospital at Peelamedu, Coimbatore
  • 2004 -Opening of hospital at Salem
  • 2007- Opening of hospital at Tirupur

Achievements/ recognition:

  • Lotus was the first Eye Hospital in South East Asia to have performed Epilasik in July 2004.
  • In the year June 2005 Lotus introduced the most advanced technology of Zyoptix Z100 and combined two superior technologies Epilasik and Zyoptix known as Zyoptix Integrated Epilasik to achieve Supervision.
  • 2012 - Life Time Achievement Award to Dr.K.Sundramoorthy by The TamilnaduDr.M.G.R.Medical University.
  • 2014 - For the sake of Governor Award to Dr.K.Sundramoorthy by Rotary International.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-4.52%
1 Week
-4.98%
1 Month
-13.50%
3 Month
-18.61%
6 Month
+4.75%
1 Year
+6.43%
2 Year
+107.74%
5 Year
+59.90%
10 Year
+477.33%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 0.81 0.08 -3.93 0.20 0.89 3.47 1.41 2.10 3.02
Return on Capital Employed (%) 0.99 0.27 -4.14 0.27 1.13 3.71 1.66 3.32 4.09
Return on Assets (%) 0.73 0.07 -3.45 0.18 0.81 3.12 1.25 1.89 2.71

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 51 51 49 49 50 51 50 51 53 53
Non Curr. Liab. 0 0 1 1 0 0 0 0 0 1
Curr. Liab. 5 7 6 5 4 7 6 6 6 7
Minority Int.
Equity & Liab. 57 59 56 55 55 57 56 57 58 61
Non Curr. Assets 49 52 51 48 48 49 49 47 45 46
Curr. Assets 7 7 5 6 7 8 7 11 14 15
Misc. Exp. not W/O 0
Total Assets 57 59 56 55 55 57 56 57 58 61

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 29 29 30 31 34 38 38 41 32 39
Other Income 1 0 0 1 1 1 1 1 1 1
Total Income 30 29 30 32 35 39 39 41 33 40
Total Expenditure -26 -26 -29 -28 -31 -34 -35 -37 -29 -33
PBIDT 4 3 2 4 4 5 4 5 4 7
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation -3 -3 -4 -4 -3 -3 -3 -3 -2 -2
Taxation 0 0 0 0 0 0 0 0 0 -1
Exceptional Items 0 0 0 0 -1 0
PAT 0 0 -2 0 0 2 1 1 2 4
Adjusted EPS 0 0 -1 0 0 1 0 1 1 2

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 2 4 4 2 3 3 6 4 5 3
Cash Fr. Inv. -3 -1 -5 -5 -1 -1 -4 -4 -1 0
Cash Fr. Finan. 0 0 -1 2 -1 0 -2 -1 0 0
Net Change -1 2 -1 0 2 2 0 -1 4 3
Cash & Cash Eqvt 0 2 1 1 2 3 4 3 7 10

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 57.68 57.68 57.68 57.71 57.74 57.74 57.74 57.74 57.74
Public 42.32 42.32 42.32 42.29 42.26 42.26 42.26 42.26 42.26
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Wed, 25 May 2022
Board Meeting Outcome for Outcome Of Board Meeting Held On May 25 2022
Outcome of Board Meeting held on May 25 2022
Wed, 25 May 2022
Dividend Updates
Final dividend of Rs0.50 per share recommended by the board subject to approval by the Shareholders in the Annual General Meeting
Wed, 25 May 2022
Related Party Transactions Half Year Ended 31/03/2022
Related Party Transactions Half year ended 31/03/2022

Technical Scans View Details

Wed, 25 May 2022
High Delivery Percentage High Delivery Percentage
Opening at High Opening at High
High Decrease 1 Month High Decrease 1 Month
High Decrease 3 Months High Decrease 3 Months
High Increase 2 Years High Increase 2 Years

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 218,615.41 911.15 +0.1%
Divi's Laboratories Ltd. 93,410.43 3,518.70 -3.9%
Cipla Ltd. 78,373.92 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. 71,774.48 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. 50,694.88 3,525.75 -2.9%
Gland Pharma Ltd. 45,552.31 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. 44,253.16 2,615.30 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 33.92 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 31.55 3,518.70 -3.9%
Cipla Ltd. Consolidated 2022-03 31.14 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.89 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 44.73 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2022-03 37.59 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 36.30 2,615.30 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.23 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 7.96 3,518.70 -3.9%
Cipla Ltd. Consolidated 2022-03 3.76 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.74 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.16 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2022-03 6.36 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 6.84 2,615.30 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 0.10 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,615.30 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 14.13 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,615.30 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 14.13 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,615.30 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 19,159.59 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,615.30 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 911.15 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,518.70 -3.9%
Cipla Ltd. Consolidated 2021-03 2,401.30 971.35 +0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,312.70 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,525.75 -2.9%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,767.85 -3.6%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,615.30 +0.9%